VM
BOLD

VHCP Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

VHCP Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$274K Hold
15,000
– – 0.29% 19
2016
Q3 		$267K Buy
+15,000
New +$228K 0.26% 22

Other funds holding BOLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VHCP Management's BOLD Position: Q4 2016 in Review

VHCP Management held its Audentes Therapeutics, Inc (BOLD) position steady in Q4 2016 at 15,000 shares worth $274K. The position accounts for 0.29% of the portfolio, ranked #19.

VHCP Management first reported a position in BOLD in Q3 2016 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold BOLD as of Q4 2016.

  • VHCP Management held 15,000 shares of Audentes Therapeutics, Inc worth $274K as of Q4 2016.
  • VHCP Management left its Audentes Therapeutics, Inc share count unchanged in Q4 2016.
  • Audentes Therapeutics, Inc made up 0.29% of VHCP Management's portfolio in Q4 2016, its #19 holding.
  • VHCP Management first reported a position in Audentes Therapeutics, Inc in Q3 2016 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.